Royalty Report: Diagnostic, Disease, Medical – Collection: 65273


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Diagnostic
  • Disease
  • Medical
  • Cancer
  • Drugs
  • Pharmaceuticals
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 65273

License Grant
The Licensor grants grants the Licensee an exclusive, royalty-bearing, non-transferable , sublicensable license under the Licensed Patents and Technical Information,  relating to molecular diagnostics for lung cancer, solely to make, have made, use, sell, offer for sale, and import the Licensed Products in the Licensed Field in the Territory during the Term.
License Property
62/163,766 Methods and Compositions for Diagnosing or Detecting Lung Cancers – Patent rights and technical information and know-how relating to molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples.
Field of Use
The Licensee  will obtain a license under such patent rights, technical information and know-how to develop and commercialize products for the non invasive cancer diagnostic testing including for lung cancer.

IPSCIO Record ID: 28771

License Grant
The University grants to the Licensee an exclusive license to practice Licensed Methods under the Patent Rights, with the right to sublicense others.
License Property
On November 10, 1992, the Licensee Licensed a patent (patent number 5,162,231) for the detection of cancers of the lung. The patent expires on November 10, 2009.

A second patent (patent number 5,391,547), dealing with treatment of cancers of the lung, was Licensed on February 21, 1995, and the patent expires on February 21, 2012.

The third Licensed patent (patent number 6,490,330) for the production of high specific activity Copper 67, was Licensed on December 3, 2002, and the patent expires on December 3, 2019.

The patents in these countries protect our rights under U.S. The following is a summary of the important terms and conditions of the License Agreement. Rights of obtained  We have obtained from the University of California, a worldwide, exclusive License for the commercial development, manufacture, use, and subLicense of the technology and to practice Licensed method for the life of the patent.

The Licensee also has the right to subLicense our rights to the Licensed patents.

Technology means technical information, know-how and data owned or controlled by the Licensor and relating to the early detection and treatment of lung cancer using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin and contained in the University's rights arising from the following a) U.S. Patent No. 5,162,231; Method Using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin for Detecting Cancers of the Lung; b) U.S. Patent No. 5,391,547; Method Using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin for Treating Cancers of the Lung; c) U.S. Patent No. 6,490,330; Production of High Specific Activity Copper -67.  

The Licensee must use best efforts to fully exploit the Licensed patent's business and market potential and to reach established milestones.

The License Agreement had certain diligence milestones that were required to be reached, including the development of the first working diagnostic test kit by January 1, 1998 and our first commercial sale by September 20, 1998. The Licensee satisfied both of these milestones before their deadline.

Field of Use
Certain Technology relating to early lung cancer detection and treatment using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin.

IPSCIO Record ID: 260378

License Grant
Licensor grants a non-exclusive license, without the right to grant or authorize sublicenses, under the Licensed Patent Rights to develop and perform the Services solely at the Facilities, and to use, and offer for sale and sell the Services to Third Parties solely in the Territory.
License Property
Licensed Patent Rights shall mean, collectively, Licensors rights in all patent applications, including provisional patent applications, heretofore or hereafter filed in the Territory;  all patents that have issued or in the future issue in the Territory from any of such patent applications, including without limitation utility models, design patents and certificates of invention; and,  all divisionals, continuations, continuations-in-part, substitutions, reissues, renewals, extensions, restorations or additions to any such patent applications and patents, in each case that claim, and only to the extent they claim, compositions, uses, methods, equipment, devices and other technology for the use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, obtained from pregnant women for prenatal diagnostic testing by whole genome massively parallel sequencing, used in the performance of the MaterniT21 PLUS Test by Licensors Laboratories as of the Effective Date, or any improvements to such test; provided, however, that the Licensed Patent Rights shall exclude any of the foregoing licensed by a University to Licensor under another agreement.

MatemiT21 PLUS Test shall mean the laboratory-developed test for the non-invasive testing of a plasma sample from a pregnant woman for the detection and diagnosis of prenatal aneuploidy and/or fetal abnormalities by use of cell-free fetal nucleic acids, currently known as the MatemiT21 PLUS test, as performed by Licensors Laboratories.

Field of Use
The Field shall mean the non-invasive detection and diagnosis of prenatal aneuploidy and fetal abnormalities by use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, obtained from pregnant women.
The MaterniT® 21 PLUS test analyzes genetic information that enters your bloodstream from the placenta.  It analyzes the amount of chromosome 21 in fetal DNA picked up from the maternal blood sample. It can detect an increased amount of chromosome 21 material which is associated with trisomy 21 (Down syndrome). It is completely non-invasive as it only involves a blood sample from the mother.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.